艾迪联合FOLFOX4方案对结肠癌患者疗效及对术后免疫功能及炎性反应的影响

doi:10.3969/j.issn.1006-6233.2017.06.022

Abstract
Figure/Table
References (18)
Related Citation (14)

Download: PDF (1421 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the effect of Addie combined with FOLFOX4 in the treatment of colon cancer and its effect on immune function and inflammatory reaction. Method: 59 patients with colon cancer in our hospital were randomly divided into the experimental group and the control group. In the control group, 28 cases were treated with FOLFOX4 chemotherapy after operation, while 31 cases in the experimental group was treated with Addie injection combined with FOLFOX4 chemotherapy after operation. The clinical efficacy of the two groups and the immune function and inflammatory reaction before and after treatment were compared. Results: The total effective rate of the experimental group was 93.5% higher than that of the control group (78.6%), and the difference was statistically significant (P<0.05); Compared with the control group, the incidence of side effects was lower in the experimental group, the difference was statistically significant (P<0.05); The levels of IgA, IgG and IgM in the experimental group were higher, and the level of IL-6 was lower, the difference was statistically significant (P<0.05). Conclusion: Addie combined with FOLFOX4 in the treatment of colon cancer patients can reduce the damage to the immune system function, clinical effect is good, and greatly improved the quality of life of patients, reduce inflammatory response.

Key words： FOLFOX4 Addie injection Colon cancer Immune function Inflammatory response

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	SONG Fei

Cite this article:

SONG Fei. Effect of Addie Combined with FOLFOX4 in the Treatment of Colon Cancer and its Effect on Immune Function and Inflammatory Reaction[J]. 河北医学, 2017, 23(6): 955-958.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2017.06.022 OR http://www.hbyxzzs.cn/EN/Y2017/V23/I6/955

[1] 陈发玲,徐伟珏,李龙至,等.不同病变范围新生儿坏死性小肠结肠炎手术干预效果分析[J].中华实用儿科临床杂志,2016,31(23):1783~1786.
[2] 陶金华,王征,刘正,等.晚期结肠癌转化治疗后行右半结肠切除1例[J].中华结直肠疾病电子杂志,2016,5(1):82~83.
[3] 单君.加速康复护理在结肠癌患者围手术期中应用的临床效果[J].中国基层医药,2016,23(24):3701~3704.
[4] 李娟娟,郑春茂,武爱娣.2015年医院抗肿瘤中药注射剂临床应用分析[J].中国药业,2016,25(16):75~77.
[5] 单君.加速康复护理在结肠癌患者围手术期中应用的临床效果[J].中国基层医药,2016,23(24):3701~3704.
[6] 陈平,袁晓琴,谢玲,等.上海市嘉定地区1265例结肠直肠息肉内镜下诊治临床资料回顾性分析[J].胃肠病学和肝病学杂志,2016,25(5):524~528.
[7] 袁炜嗣,庄丹,林锡汉,等.腹腔镜与传统开腹手术在结肠癌根治术中治疗近期疗效观察[J].黑龙江医学,2016,29(6):1210~1212.
[8] 米希茂,MiXimao.Ⅱ~Ⅲ期大肠癌根治术后两种辅助化疗方案临床疗效及安全性比较[J].中国基层医药,2016,23(6):867~869.
[9] 张腾腾,杨振.康艾注射液体外对结肠癌Lovo细胞凋亡和增殖的影响[J].中国基层医药,2016,23(16):2425~2428.
[10] 王俊芳,张琴,毛莉,等.腹腔内贝伐珠单抗联合腹腔热灌注化疗治疗卵巢癌腹腔积液的疗效和安全性[J].中国基层医药,2016,23(8):1228~1231.
[11] 祁峰,陈苏蓉,尹存林,等.临床药师干预对抗肿瘤药物临床合理应用的影响[J].中国基层医药,2017,24(3):358~364.
[12] 何玲,张倩倩,吕晓云,等.丹参水提液对染镉大鼠血清超氧化物歧化酶、丙二醛、总抗氧化能力的影响[J].中国基层医药,2016,23(23):3620~3624.
[13] 仇春丽,陈云超,刘娜,等.超声介导自制纳米泡联合顺铂对小鼠H22肿瘤抑制作用的研究[J].中华超声影像学杂志,2016,25(2):173~177.
[14] 王辉.血必净与乌司他丁辅助治疗慢性阻塞性肺疾病急性加重期的效果比较[J].中国基层医药,2016,23(6):932~934.
[15] 王丽.类风湿关节炎患者血清白细胞介素6、白细胞介素17、粒细胞-巨噬细胞集落刺激因子和肿瘤坏死因子α水平检测的临床意义[J].中国基层医药,2016,23(16):2454~2457.
[16] 杨晓珍,张晓勇,刘海春,等.肝动脉化疗栓塞联合射频消融治疗肝癌疗效及预后分析[J].中国基层医药,2016,23(17):2609~2612.
[17] 马贵欣,MaGuixin.小剂量肝素钠联合低分子肝素钠和重组人尿激酶原治疗急性心肌梗死19例临床观察[J].中国基层医药,2016,23(14):2222~2224.
[18] 张蕴,黄文烨,张建,等.人粒细胞-巨噬细胞集落刺激因子联合R-CHOP方案治疗弥漫大B细胞淋巴瘤的临床疗效研究[J].中国基层医药,2016,23(6):805~809.